Quality Data Services
Give us your tightest timeline and we will speed regulatory submissions with efficient, high-quality clinical trial data and insightful analyses.
Clinical Trial Data Expertise
That Reduces Risk.
Meet regulatory requirements—every time—regardless of phase, therapeutic area, size of study or method of data capture. Firma’s clinical experience means we deliver high-quality and statistically sound data, fast and efficient database integrations, and summary analyses that you can count on.
Speed, Accuracy & Trust
Experience means we can deliver the speed, accuracy and consistency you need. Our PhD- and MS-level professionals adhere to a single set of global standard operating procedures, offering their detailed and extensive knowledge of pharmaceutical development to benefit your entire data management and biostatistics planning, execution, and analysis.
Submission success depends on the integrity and cleanliness of your data. We deliver high-quality results with a QA process that includes QC and double programming.
Fast, Flexible Workflows
Expedite trial start with our four-week database build. We consistently achieve a database build-and-release timeline that is 2x faster than the industry standard.
Medical, data management, and biostatistics work together, starting with physician-led protocol training for each project, so you always get cross-functional intelligence.
At risk of missing an agency submission? Firma can implement database builds, program and generate tables, and create study report shells to help studies meet original timelines.
Firma’s Scientific Advisory Board
Leadership. Strategy. Guidance.
Firma’s biometrics team is able to expand our reach and our expertise by collaborating with top experts in the field through our Scientific Advisory Board. Board members are academics and industry professionals with expertise in everything from oncology to bayesian statistics to regulations and compliance.
“Firma delivers when they commit to a study. The quality of their work is always high, and they have never missed a timeline regardless of protocol amendments throughout the study lifecycle.”